Synergistic induction of 1,25,-dihydroxyvitamin D3-and all-trans-retinoic acid-induced differentiation of HL-60 leukemia cells by yomogin, a sesquiterpene lactone from Artemisia princeps

Planta Medica

Volumn 68, Issue 10, 2002, Pages 886-890

  Kim, Seung Hyun ^a   Kim, Tae Sung ^a,b  

^a Chonnam National University   (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

1,25 dihydroxyvitamin D3; All trans retinoic acid; Cancer; Differentiation; Yomogin

Indexed keywords

CALCITRIOL; RETINOIC ACID; SESQUITERPENE LACTONE; UNCLASSIFIED DRUG; YOMOGIN;

ARTEMISIA PRINCEPS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HL 60; CELL VIABILITY; CONTROLLED STUDY; CYTOFLUOROMETRY; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST;

ANTINEOPLASTIC AGENTS; ARTEMISIA; CALCITRIOL; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NITRIC OXIDE SYNTHASE; PHYTOTHERAPY; SESQUITERPENES; SESQUITERPENES, EUDESMANE; TRETINOIN;

ARTEMISIA; ARTEMISIA PRINCEPS;

EID: 0036774868     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-34937     Document Type: Article

References (17)

1. Drexier HG, Quentmeier H, MacLeod RA, Uphoff CC, Hu ZB. Leukemia celllines: In vitro models for the study of acute promyelocytic leukemia. Leukemia Research 1995; 19: 681-91
2. Quintero A, Pelcastre A, Solano JD. Antitumoral activity of new pyrimidine derivatives of sesquiterpene lactones. Journal of Pharmacy and Pharmaceutical Science 1999; 2: 108-12
3. Ryu JH, Lee HJ, Jeong YS, Ryu SY, Han YN. Yomogin, an inhibitor of nitric oxide production in LPS-activated macrophages. Archives of Pharmacal Research 1998; 21: 481-4
4. 3. Leukemia Research 1998; 22: 153-61
5. James SY, Williams MA, Newland AC, Colston KW. Leukemia cell differentiation: Cellular and molecular interactions of retinoids and vitamin D. General Pharmacology 1999; 32: 143-54
6. Ryu SY, Oak MH, Kim KM. Yomogin inhibits the degranulation of mast cells and the production of the nitric oxide in activated RAW 264.7 cells. Planta Medica 2000: 66: 171-3
7. Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC. Normal functional characteristics of cultured human promyelocytic leukemia cells (HL-60) after induction of differentiation by dimethyl sulfoxide. Journal of Experimental Medicine 1979; 149: 969-74
8. Kansas GS, Muirhead MJ, Dailey MO. Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood 1990; 76: 2483-92
9. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-3
10. Breitman TR, He RY. Combinations of retinoic acid with sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. Cancer Research 1990; 50: 6268-73
11. 3 and tumor necrosis factor α Experimental Hematology 1991; 19: 1025-30
12. 3 for growth inhibition and differentiation induction of human myelomonocytic leukemia cells by tretinoin tocoferil, a α-tocopherol ester of all-trans-retinoic acid. Blood 1996; 87: 3384-94
13. 3- and all-trans-retinoic acid-induced differentiation of human promyelocytic leukemia HL-60 cells. European Journal of Pharmacology 2001; 420: 83-90
14. 3: Possible relationship to NF-κB. Leukemia 1997; 11: 1546-53
15. 3. Cancer Letter 1998; 125: 157-64
16. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New England Journal of Medicine 1991; 324: 1385-93
17. 3 and skin diseases. Archieves of Dermatological Research 1992; 284: 30-6